SC 13G/A: Xilio Therapeutics, Inc.
Ticker: XLO · Form: SC 13G/A · Filed: Jul 31, 2024 · CIK: 1840233
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Xilio Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 1,384 words · 6 min read · ~5 pages · Grade level 10.4 · Accepted 2024-07-31 07:46:49
Key Financial Figures
- $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
Filing Documents
- sc13ga_073124.htm (SC 13G/A) — 65KB
- exhibit991_073124.htm (EX-99.1) — 2KB
- exhibit992_073124.htm (EX-99.2) — 7KB
- 0001395064-24-000156.txt ( ) — 76KB
(a) Name of issuer
Item 1(a) Name of issuer Xilio Therapeutics, Inc. (the "Issuer").
(b) Address of issuer's principal executive offices
Item 1(b) Address of issuer's principal executive offices 828 Winter Street, Suite 300, Waltham, MA 02451
(a) Name of person filing
Item 2(a) Name of person filing Takeda Pharmaceutical Company Limited Takeda Ventures, Inc.
(b) Address of principal business office or, if none, residence
Item 2(b) Address of principal business office or, if none, residence Takeda Pharmaceutical Company Limited – 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo M0 103-8668, Japan Takeda Ventures, Inc. – 500 Kendall Street, Cambridge, MA 02142, USA
(c) Citizenship
Item 2(c) Citizenship Takeda Pharmaceutical Company Limited is a corporation formed under the laws of Japan. Takeda Ventures, Inc. is a corporation formed under the laws of the State of Delaware.
(d) Title of class of securities
Item 2(d) Title of class of securities Common Stock, par value $0.0001 per share
(e) CUSIP No
Item 2(e) CUSIP No. 98422T100
If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a
Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a Not applicable.
Ownership
Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned See the responses in Row 9 on the attached cover pages. (b) Percent of class See the responses in Row 11 on the attached cover pages. Page 4 of 6 pages (c) Number of shares as to which the person has (i) Sole power to vote or to direct the vote See the responses in Row 5 on the attached cover pages. (ii) Shared power to vote or to direct the vote See the responses in Row 6 on the attached cover pages. (iii) Sole power to dispose or to direct the disposition of See the responses in Row 7 on the attached cover pages. (iv) Shared power to dispose or to direct the disposition of See the responses in Row 8 on the attached cover pages. The percentages used herein and in this Item 4 are calculated based on 36,912,373 shares of Common Stock issued and outstanding as of May 10, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 14, 2024.
Ownership of 5 Percent or Less of a Class
Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .
Ownership of More than 5 Percent on Behalf of Another Person
Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit 99.1.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group. Not applicable.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group. Not applicable.
Certifications
Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Page 5 of 6 pages
Signatures
Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated July 31, 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED By s Yoshihiro Nakagawa Name Yoshihiro Nakagawa Title Global General Counsel TAKEDA VENTURES, INC. By s Max Heuer Name Max Heuer Title Assistant Secretary Page 6 of 6 pages INDEX TO EXHIBITS Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding compan y Exhibit 99.2 Joint Filing Agreement